Document Detail


The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling.
MedLine Citation:
PMID:  22532226     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
This study reports on the C-terminal fragment of the 11S proteasome activator complex (PA28 or Reg alpha), a novel ovarian-specific biomarker of early and late stages of ovarian cancer (OVC) relapse, in patient biopsies after chemotherapy. A total of 179 tissue samples were analyzed: 8 stage I, 55 stage III-IV, 10 relapsed serous carcinomas, 25 mucinous carcinomas and 12 borderline and 68 benign ovarian tissue samples. This fragment was detected by MALDI mass spectrometry profiling in conjunction with a novel extraction method using hexafluoroisopropanol (1,1,1,3,3,3-hexafluoro-2-propanol; HFIP) solvents for protein solubilization and by immunohistochemistry using a specific antibody directed against the C-terminal fragment of PA28. Due to its specific cellular localization, this fragment is a suitable candidate for early OVC diagnosis, patient prognosis and follow-up during therapy and discriminating borderline cancers. Statistical analyses performed for this marker at different OVC stages reflect a prevalence of 77.66 ± 8.77 % (with a correlation coefficient value p < 0.001 of 0.601 between OVC and benign tissue). This marker presents a prevalence of 88 % in the case of tumor relapse and is detected at 80.5 % in stage I and 81.25 % ± 1.06 in stage III-IV of OVC. The correlation value for the different OVC stages is p < 0.001 of 0.998. Taken together, this report constitutes the first evidence of a novel OVC-specific marker.
Authors:
Rémi Longuespée; Charlotte Boyon; Céline Castellier; Amélie Jacquet; Annie Desmons; Olivier Kerdraon; Denis Vinatier; Isabelle Fournier; Robert Day; Michel Salzet
Related Documents :
21061346 - Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mit...
22002506 - Prognostic factors and survival in a prospective cohort of patients with high-grade gli...
7478436 - 5-fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellul...
8922196 - Mitomycin c plus vindesine plus etoposide (mev) versus mitomycin c plus vindesine plus ...
19309506 - Tle3 as a candidate biomarker of response to taxane therapy.
23499016 - Recurrence after operative management of intrahepatic cholangiocarcinoma.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-25
Journal Detail:
Title:  Histochemistry and cell biology     Volume:  -     ISSN:  1432-119X     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9506663     Medline TA:  Histochem Cell Biol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Laboratoire de Spectrométrie de Masse Biologique Fondamentale et Appliquée, Université Nord de France, EA 4550, Université de Lille 1, Cité Scientifique, 59650, Villeneuve D'Ascq, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors.
Next Document:  A model-based decision support system for critiquing mechanical ventilation treatments.